Institutional investors purchased a net $582.1 thousand shares of ENZN during the quarter ended December 2012, and now own 85.23% of the total float, a percentage that is typical for companies in the Biotechnology industry.
| Other institutional | 63.81% |
| Individual stakeholders | 23.57% |
| Mutual fund holders | 21.42% |